Hildur Sóley Sveinsdóttir, Christian Christensen, Haraldur Þorsteinsson, Perrine Lavalou, Matthew O Parker, Alena Shkumatava, William H J Norton, Emile Andriambeloson, Stéphanie Wagner, Karl Ægir Karlsson
ADHD is a highly prevalent neurodevelopmental disorder. The first-line therapeutic for ADHD, methylphenidate, can cause serious side effects including weight loss, insomnia, and hypertension. Therefore, the development of non-stimulant-based therapeutics has been prioritized. However, many of these also cause other effects, most notably somnolence. Here, we have used a uniquely powerful genetic model and unbiased drug screen to identify novel ADHD non-stimulant therapeutics. We first found that adgrl3.1 null (adgrl3...
November 18, 2022: Neuropsychopharmacology